Quantcast

Latest Olanzapine Stories

2009-09-02 09:48:00

PHILADELPHIA, Sept. 2 /PRNewswire/ -- Pfizer, Inc. announced today it has agreed to plead guilty to criminal conduct and to pay more than $2 billion in criminal and civil fines, penalties and damages to settle allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for four of its drugs. The settlement is the largest qui tam settlement in U.S....

2009-08-26 01:00:00

OSAKA, Japan, and FORT LEE, N.J., Aug. 26 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo. "We are pleased with...

2009-07-24 09:07:00

KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its investigational agent SAPHRIS(R) (asenapine) met the primary endpoint over one year of treatment in an extension study in patients with predominant, persistent negative symptoms of schizophrenia. Negative symptoms of schizophrenia include apathy, lack of emotion and poor social functioning, among others. In the study, these symptoms were assessed using the validated...

2009-07-23 07:00:00

WALTHAM, Mass., July 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients. Abilify is second to risperidone (Janssen's Risperdal, generics) in first and second lines of therapy and leads other...

167b538f310d0a90f8e7a8e9b3562fca
2009-07-02 06:25:00

Three interrelated, international studies examining the genetic aspects of schizophrenia and bipolar disorder have found some 30,000 gene variations that may contribute to the mental illnesses.  Researchers say the data paints a far more complex picture of the diseases"”as well as treatment and diagnosis"”than had been previously understood. The three research projects examined DNA samples from a total of 10,000 people with schizophrenia and another 20,000 without.  The...

2009-06-10 17:30:00

ADELPHI, Md., June 10 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted that Zyprexa(R) (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old. The panel supported the FDA and Lilly's position that if Zyprexa is approved for the two indications, prescribers...

d4e2a612837dd6de7ccdeebd181ed5981
2009-06-05 14:48:00

The US Food and Drug Administration announced on Friday that it is investigating the approval of three popular antipsychotic drugs for children. The three drugs, currently marketed for adult use by AstraZeneca, Pfizer and Eli Lilly and Co, appear to be beneficial in children and adolescents, but FDA regulators said they must determine if the drugs pose a greater risk to younger patients. An agency panel is set to meet next week in order to weigh the risks of the psychiatric drugs in children...

2009-05-18 12:30:00

Three-year data show olanzapine LAI safety findings consistent with oral olanzapine except for injection-related events INDIANAPOLIS, May 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company presented today data on the short- and long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of adults with schizophrenia or schizoaffective disorder. Olanzapine LAI is an investigational formulation that combines the atypical antipsychotic Zyprexa(R) (olanzapine) with...

2009-03-29 12:00:00

SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia. In Study HBBI, neither LY2140023 monohydrate, nor the comparator molecule olanzapine, known to be more effective than placebo, separated from placebo. In this particular study, Lilly observed a...

2009-03-27 20:56:07

U.S. doctors have tested a treatment for weight gain caused by some anti-psychotic medications. The randomized, double-blind, placebo-controlled trial, published in Biological Psychiatry, evaluated an add-on treatment known as modafinil -- a drug currently used to increase wakefulness in those with sleep disorders. All of the study subjects -- normal volunteers -- received olanzapine -- commonly used to treat psychotic disorders. Half also received modafinil treatment while the other half...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related